Etanercept biosimilar - Merck & Co./Samsung Bioepis
Alternative Names: Benepali; BRENZYS; Brenzys; ETICOVO; SB-4Latest Information Update: 21 Sep 2022
Price :
$50 *
At a glance
- Originator Samsung Bioepis
- Developer Biogen; Merck & Co; Samsung Bioepis
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Non-radiographic axial spondyloarthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
- Registered Psoriasis
Most Recent Events
- 15 Aug 2022 Launched for Juvenile rheumatoid arthritis in Sweden (SC)
- 15 Aug 2022 Launched for Non-radiographic axial spondyloarthritis in Sweden (SC)
- 15 Aug 2022 Launched for Psoriatic arthritis in Sweden (SC)